iCAN Group for Social Support

Phase-Based Progress Estimates
Charlie Center, Austin, TX
Social Support+5 More
iCAN Group - Behavioral
All Sexes
What conditions do you have?

Study Summary

People experiencing homelessness (PEH) are at exceptionally high risk of frequent emergency department (ED) and hospital use, poor functional outcomes, and increased morbidity and mortality from poorly managed chronic health conditions and complex social needs. Evidence-based interventions of particular promise for reducing ED and hospital utilization and improving health outcomes and meeting social needs involve:1) providing care in the community to overcome barriers including transportation and fear of stigmatization; 2) coordination of care transitions following ED or hospital discharge to improve access to needed community supports and reduce the risk of readmission; and 3) using mHealth technology to link PEH with appropriate community-based health and social services. This project builds on evidence from two feasibility studies in order to integrate and test a mHealth intervention, comprised of GPS technology and text messaging components, into a community setting to connect PEH with a community-based case manager and healthcare and social services. Our hypothesis is that integrating the mHealth intervention into an established, trusted navigation center for PEH will mitigate barriers to care and gaps in the care continuum resulting in decreased ED and hospital use and improved health outcomes and attainment of social needs. The study aim is to conduct a stratified RCT to compare a mHealth intervention with usual care community-based case management to examine the impact on healthcare utilization (primary outcome), medication adherence, social support, psychological distress and social needs attainment (secondary outcomes) in PEH.

Eligible Conditions

  • Social Support
  • Pyschological Distress
  • Adherence, Medication
  • Attainment of Social Needs (i.e., Housing, Employment, Receipt of Benefits)
  • Number of Emergency Department and Hospital Visits Among Adults Experiencing Homelessness

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Social need attainment will be assessed at baseline, 1, 3, 5, and 6 months post-enrollment.

Month 6
Medication Adherence
Month 12
Number of emergency department (ED) and hospital visits
Month 6
Process measures in iCAN group
Month 6
Psychological Distress
Month 6
Social Needs Attainment
Month 6
Social Support
The technology and case manager assessment will occur at the 6-month post-enrollment visit.
Technology and Case Manager Assessment

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual Care Control (UCC)
1 of 2
iCAN Group
1 of 2
Active Control
Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: iCAN Group · No Placebo Group · N/A

iCAN Group
Experimental Group · 1 Intervention: iCAN Group · Intervention Types: Behavioral
Usual Care Control (UCC)NoIntervention Group · 1 Intervention: Usual Care Control (UCC) · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: social need attainment will be assessed at baseline, 1, 3, 5, and 6 months post-enrollment.
Closest Location: Charlie Center · Austin, TX
Photo of Austin  1Photo of Austin  2Photo of Austin  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Social Support
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a score of at least 4 on the REALM-SF health literacy measure

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.